Filing Flows › Janux Therapeutics (JANX) › Q1 2026
Janux Therapeutics (JANX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Janux Therapeutics (JANX) reported revenue of $3.7M for the first quarter 2026 (Q1 2026). Operating margin was -916.5%, net loss $24.4M (652.6% of revenue).
Janux Therapeutics, Q1 2026: revenue $3.7M, operating margin -916.5%, net loss $24.4M, operating cash flow −$12.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.7M | — | — |
| Operating profit | −$34.2M | — | — |
| Net earnings | −$24.4M | — | — |
| Operating cash flow | −$12.3M | — | — |
What changed
Revenue was $3.7M in Q1 2026.
Operating costs exceeded revenue by $34.2M, an operating margin of -916.5%. The quarter ended with a net loss of $24.4M. Non-operating items added $9.9M, -40% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$12.3M. Non-cash charges added back $469K of depreciation and $9.3M of share-based compensation. Working capital and other items added $2.3M. Capital expenditures of $273K exceeded it, leaving free cash flow of −$12.6M.
Questions
What was Janux Therapeutics' revenue in the first quarter 2026?
Janux Therapeutics (JANX) reported revenue of $3.7M for the first quarter 2026 (Q1 2026).
Was Janux Therapeutics profitable in the first quarter 2026?
Operating loss was $34.2M (-916.5% of revenue) and net loss $24.4M.
Source: Janux Therapeutics 10-Q on SEC EDGAR.